Melola Discovery

← Melola Discovery

Journal

Penatalaksanaan Program Pengendalian Tuberkulosis Multi Drug Resistant

HIGEIA (Journal of Public Health Research and Development) · Vol. 4 No. Special (2020) · pp. 887–897

DOI
10.15294/higeia.v4iSpecial
ISSN
2541-5581, 2541-5603
Published
2020-12-30
Publisher
Universitas Negeri Semarang
Language
eng

Abstract

Abstrak Multidrug Resistance Tuberculosis TB (atau TB MDR) adalah salah satu jenis resistensi bakteri TB terhadap minimal dua obat anti TB lini pertama, yaitu Isoniazid dan Rifampicin yang merupakan dua obat TB yang paling efektif. Pengobatan TB Resistan Obat ditetapkan menjadi bagian dari program Pengendalian TB nasional. Total kasus Tuberkulosis Multi Drug Resistant (TB MDR) di Kota Semarang dari tahun 2014 s.d tahun 2018 sebanyak 165 kasus. Dikaitkan dengsan proporsi kejadian TB MDR pada kasus TB Baru dan TB Kambuh di tahun 2018 terdapat 71 kasus baru TB MDR. Angka kesembuhan kasus TB Kota Semarang dalam kurun waktu 5 (lima) tahun terakhir tidak pernah mencapai target nasional, yang tertinggi sebesar 65% CR di tahun 2017, yang terendah sebesar 64 % di tahun 2013. Rata-rata pencapaian CR pertahunnya baru sebesar 18,32% di bawah target CR nasional. Puskesmas Bandarharjo merupakan salah satu fasilitas kesehatan tingkat pertama yang telah melaksanakan program pengendalaian TB MDR. Pasien yang terdata pada tahun 2019 sebanyak 10 kasus. Tujuan penelitian ini adalah untuk mengetahui penatalaksanaan program pengendalian Tuberkulosis Multi Drug Resistant (TB MDR) di Puskesmas Bandarharjo Kota Semarang. Jenis dan rancangan penelitian yang digunakan dalam penelitian ini adalah deskripstif kualitatif. Penelitian dilakukan pada bulan oktober sampai dengan novemver 2019. Hasil penelitian menunjukkan bahwa penatalaksanaan program pengendalian TB MDR di Puskesmas Bandarharjo sudah dilaksanakan dengan baik tetapi belum maksimal. Hal ini dilihat dari kurangnya tersedia sarana dan prasarana yang mendukung, serta tidak adanya penyuluhan yang diberikan kepada petugas TB dan PMO. Abstract Multidrug Resistance Tuberculosis TB (or MDR TB) is one type of TB bacterial resistance to at least two first-line anti-TB drugs, namely Isoniazid and Rifampicin which are the two most effective TB drugs. Drug-resistant TB treatment is determined to be part of the national TB Control program. Total cases of Multi Drug Resistant Tuberculosis (MDR TB) in Semarang City from 2014 to 2018 were 165 cases. Associated with the proportion of MDR TB cases in New TB and Kambuh TB cases in 2018 there were 71 new MDR TB cases. The cure rate of Semarang City TB cases in the past 5 (five) years has never reached the national target, the highest of 65% CR in 2017, the lowest of 64% in 2013. The average annual CR achievement is only 18, 32% below the national CR target. The Bandarharjo Health Center is one of the first-level health facilities that has implemented an MDR TB control program. There are 10 patients recorded in 2019. The purpose of this study was to determine the management of the Multi Drug Resistant Tuberculosis (MDR TB) control program at the Bandarharjo Health Center in Semarang City. The type and design of the study used in this study is qualitative descriptive. The study was conducted from October to November 2019. The results showed that the management of the MDR TB control program at the Bandarharjo Puskesmas was well implemented but not yet optimal. This can be seen from the lack of available supporting facilities and infrastructure, as well as the lack of counseling given to TB and PMO officers.

Collaboration network of the authors

40 authors · 96 co-authorship links · showing the 40 most connected

Hover or tap a name to highlight its co-authors. Double-click to open the author's page.

  • Institut Agama Islam Negeri Kendari
  • Affiliation unknown
  • Different organisations
  • Same organisation
  • Affiliation unknown
  • Thicker line = more joint articles · bigger circle = more articles
Show as table
Co-authorOrganisationJoint articles
Dyah Mahendrasari SukendraAffiliation unknown3
Bertakalswa HermawatiAffiliation unknown2
Sri Ratna RahayuAffiliation unknown2
Mahalul AzamAffiliation unknown2
Yunita Dyah Puspita SantikAffiliation unknown2
Donna Ayuk TriyantoAffiliation unknown1
Arindita ReinissaAffiliation unknown1
Nurmawati NurmawatiAffiliation unknown1
Alfina Dewi NugrahanyAffiliation unknown1
Mira Andri AstutiAffiliation unknown1
Trinanda Agustina Sapta NingrumAffiliation unknown1
Ismah Dwi CahyaniAffiliation unknown1
Alya AgustiniAffiliation unknown1
Umy Hani ShalamahAffiliation unknown1
Ni'matul UlumiaAffiliation unknown1
Anisa FitriInstitut Agama Islam Negeri Kendari1
Arvia Dhitya MaharhaniAffiliation unknown1
Malikhatul MustafidahAffiliation unknown1
Istiqomah IstiqomahAffiliation unknown1
Nita Safaatul InsiyahAffiliation unknown1
Jihan Mega LestariAffiliation unknown1
Widya Hary CahyatiAffiliation unknown1
Kaori Risma Fauzia NugrohoAffiliation unknown1
Indra Aditya BaskaraAffiliation unknown1
Hanif Pandu SuhitoAffiliation unknown1
Bambang WahyonoAffiliation unknown1
Intan ZainafreeAffiliation unknown1
Chatila MaharaniAffiliation unknown1
Nadia SyukriaAffiliation unknown1
Maria M. Rosaria PatriajatAffiliation unknown1
Mohammad Abdul HakamAffiliation unknown1
Rahma DefiAffiliation unknown1
Dian LatifianiAffiliation unknown1
Yustina Dhian NovitaAffiliation unknown1
Yulanda Datu FebrianiAffiliation unknown1
Meliana LatifahAffiliation unknown1
Samuel KristianAffiliation unknown1
Bambang Wahyono WahyonoAffiliation unknown1

Affiliations come from OpenAlex; journal OAI-PMH metadata carries none. Authors without an OpenAlex ID are matched by name, which can merge or split people.

Metadata source: OAI-PMH (metadata jurnal) https://journal.unnes.ac.id/sju/index.php/higeia/oai, first harvested 5 Nov 2026, last seen 8 Nov 2026.
Original metadata (oai_dc)
<oai_dc:dc xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/  http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en-US">Penatalaksanaan Program Pengendalian Tuberkulosis Multi Drug Resistant</dc:title>
	<dc:creator>Komalasari, Wiwid</dc:creator>
	<dc:creator>Indrawati, Fitri</dc:creator>
	<dc:description xml:lang="en-US">Abstrak
Multidrug Resistance Tuberculosis TB (atau TB MDR) adalah salah satu jenis resistensi bakteri TB terhadap minimal dua obat anti TB lini pertama, yaitu Isoniazid dan Rifampicin yang merupakan dua obat TB yang paling efektif. Pengobatan TB Resistan Obat ditetapkan menjadi bagian dari program Pengendalian TB nasional. Total kasus Tuberkulosis Multi Drug Resistant (TB MDR) di Kota Semarang dari tahun 2014 s.d tahun 2018 sebanyak 165 kasus. Dikaitkan dengsan proporsi kejadian TB MDR pada kasus TB Baru dan TB Kambuh di tahun 2018 terdapat 71 kasus baru TB MDR. Angka kesembuhan kasus TB Kota Semarang dalam kurun waktu 5 (lima) tahun terakhir tidak pernah mencapai target nasional, yang tertinggi sebesar 65% CR di tahun 2017, yang terendah sebesar 64 % di tahun 2013. Rata-rata pencapaian CR pertahunnya baru sebesar 18,32% di bawah target CR nasional. Puskesmas Bandarharjo merupakan salah satu fasilitas kesehatan tingkat pertama yang telah melaksanakan program pengendalaian TB MDR. Pasien yang terdata pada tahun 2019 sebanyak 10 kasus. Tujuan penelitian ini adalah untuk mengetahui penatalaksanaan program pengendalian Tuberkulosis Multi Drug Resistant (TB MDR) di Puskesmas Bandarharjo Kota Semarang. Jenis dan rancangan penelitian yang digunakan dalam penelitian ini adalah deskripstif kualitatif. Penelitian dilakukan pada bulan oktober sampai dengan novemver 2019. Hasil penelitian menunjukkan bahwa penatalaksanaan program pengendalian TB MDR di Puskesmas Bandarharjo sudah dilaksanakan dengan baik tetapi belum maksimal. Hal ini dilihat dari kurangnya tersedia sarana dan prasarana yang mendukung, serta tidak adanya penyuluhan yang diberikan kepada petugas TB dan PMO.
&amp;nbsp;
Abstract
Multidrug Resistance Tuberculosis TB (or MDR TB) is one type of TB bacterial resistance to at least two first-line anti-TB drugs, namely Isoniazid and Rifampicin which are the two most effective TB drugs. Drug-resistant TB treatment is determined to be part of the national TB Control program. Total cases of Multi Drug Resistant Tuberculosis (MDR TB) in Semarang City from 2014 to 2018 were 165 cases. Associated with the proportion of MDR TB cases in New TB and Kambuh TB cases in 2018 there were 71 new MDR TB cases. The cure rate of Semarang City TB cases in the past 5 (five) years has never reached the national target, the highest of 65% CR in 2017, the lowest of 64% in 2013. The average annual CR achievement is only 18, 32% below the national CR target. The Bandarharjo Health Center is one of the first-level health facilities that has implemented an MDR TB control program. There are 10 patients recorded in 2019. The purpose of this study was to determine the management of the Multi Drug Resistant Tuberculosis (MDR TB) control program at the Bandarharjo Health Center in Semarang City. The type and design of the study used in this study is qualitative descriptive. The study was conducted from October to November 2019. The results showed that the management of the MDR TB control program at the Bandarharjo Puskesmas was well implemented but not yet optimal. This can be seen from the lack of available supporting facilities and infrastructure, as well as the lack of counseling given to TB and PMO officers.</dc:description>
	<dc:publisher xml:lang="en-US">Universitas Negeri Semarang</dc:publisher>
	<dc:date>2020-12-30</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en-US">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://journal.unnes.ac.id/sju/higeia/article/view/37527</dc:identifier>
	<dc:identifier>10.15294/higeia.v4iSpecial 4.37527</dc:identifier>
	<dc:source xml:lang="en-US">HIGEIA (Journal of Public Health Research and Development); Vol 4 No Special 4 (2020): HIGEIA: December 2020; 887-897</dc:source>
	<dc:source>2541-5581</dc:source>
	<dc:source>2541-5603</dc:source>
	<dc:source>10.15294/higeia.v4iSpecial 4</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://journal.unnes.ac.id/sju/higeia/article/view/37527/18010</dc:relation>
	<dc:rights xml:lang="en-US">Copyright (c) 2020 HIGEIA (Journal of Public Health Research and Development)</dc:rights>
</oai_dc:dc>